Golimumab Preserves Insulin Production in Type 1 Diabetes

The human monoclonal antibody golimumab (Symponi) preserved endogenous insulin secretion in patients with new-onset type 1 diabetes and reduced their exogenous insulin requirements at 1 year, newly published phase 2 data indicate. Results from the multicenter, double-blind, placebo-controlled trial were first reported as a poster at the virtual American Diabetes Association (ADA) 80th Scientific Sessions…Continue Reading